The long, tortuous race to market a therapeutic based on RNA interference (RNAi) may be nearing its end. Ken Garber reports.
This is a preview of subscription content, log in via an institution to check access.
References
Garber, K. Nat. Biotechnol. 34, 1213–1214 (2016)
Elbashir, S.M. et al. Nature 411, 494–498 (2001).
Zuckerman, J.E. et al. Proc. Natl. Acad. Sci. USA 111, 11449–11454 (2014).
Tabernero, J. et al. Cancer Discov. 3, 406–417 (2013).
Coelho, T. et al. N. Engl. J. Med. 369, 819–829 (2013).
Nair, J.K. et al. J. Am. Chem. Soc. 136, 16958–16961 (2014).
Fitzgerald, K. et al. N. Engl. J. Med. 376, 41–51 (2017).
Grimm, D. et al. Nature 441, 537–541 (2006).
Shen, W., Liang, X.H., Sun, H. & Crooke, S.T. Nucleic Acids Res. 43, 4569–4578 (2015).
Janas, M.M. et al. Nucleic Acids Ther. doi:1089/nat.2016.0639 (2016).
Pasi K.J. et al. Blood 128, 1397 (2016).
Ragni, M.V. Blood 128, 2572 (2016).
Sardh, E. et al. Blood 128, 2318 (2016).
Meade, B.R. et al. Nat. Biotechnol. 32, 1256–1261 (2014).
Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A. & Davis, M.E. Proc. Natl. Acad. Sci. USA 104, 15549–15554 (2007).
Semple, S.C. et al. Nat. Biotechnol. 28, 172–176 (2010).
Judge, A. & MacLachlan, I. Hum. Gene Ther. 19, 111–124 (2008).
Barros, S.A. & Gollob, J.A. Adv. Drug Deliv. Rev. 64, 1730–1737 (2012).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Worth the RISC?. Nat Biotechnol 35, 198–202 (2017). https://doi.org/10.1038/nbt.3810
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3810
- Springer Nature America, Inc.
This article is cited by
-
Tapping the RNA world for therapeutics
Nature Structural & Molecular Biology (2018)
-
With Alnylam's amyloidosis success, RNAi approval hopes soar
Nature Biotechnology (2017)